Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.40
Previous CloseN/A
Volume145.39K
Average Volume (3M)89.38K
Market Cap
C$9.45M
Enterprise ValueC$13.07M
Total Cash (Recent Filing)C$434.80K
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Annual Net LossThe improvement in annual net loss indicates some progress in controlling expenses or reducing losses. However, this remains only an early positive because the company has no revenue, remains unprofitable, and still requires a sustainable operating model.
Debt ReductionLower debt than in 2025 modestly reduces balance-sheet pressure and may limit future interest or repayment burdens. The benefit is constrained by the company’s small asset base, negative equity, and limited ability to fund operations internally.
Improved Cash BurnA lower cash-burn rate could extend financial runway and provide more time to develop the business or secure funding. The improvement is not yet sufficient to establish self-sufficiency because operating cash flow and free cash flow remain negative.
Bears Say
No Revenue And Continuing LossesThe absence of a revenue base leaves the company without demonstrated commercial traction or internally generated funding. Continued negative gross profit, EBIT, EBITDA, and net income make long-term sustainability dependent on future product success or external capital.
Negative Equity And Limited Capital CushionNegative equity reflects accumulated financial losses and weakens the balance sheet’s ability to absorb further setbacks. With meaningful debt relative to assets, financial flexibility is limited and future recapitalization could create material dilution for existing holders.
Persistent Negative Free Cash FlowPersistent negative free cash flow shows that operations do not currently finance the business. Continued cash burn increases reliance on financing, and funding needs may remain recurring unless the company establishes revenue, improves margins, or materially reduces expenses.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.12 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$9.45M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Nov 26, 2026 which is in 90 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Jun 18, 2026. The company reported C$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.007.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of C$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Technical Analysis
BetterLife Pharma
―
Helus Pharma
―
―
Bright Minds Biosciences
―
MYND Life Sciences
―